Cartesian Therapeutics (RNAC) Capital Expenditures (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Capital Expenditures of $27000.0 for Q1 2026, down 97.49% year-over-year from $1.1 million in Q1 2025, and down 99.49% quarter-over-quarter from $5.3 million in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Capital Expenditures (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Capital Expenditures for 12 consecutive years, with $27000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 97.49% year-over-year to $27000.0; the TTM figure through Mar 2026 stood at $4.4 million (up 129.24% YoY), while the FY2025 annual figure was $5.5 million, up 543.92% from the prior year.
- Capital Expenditures fell to $27000.0 in Q1 2026 per RNAC's latest filing, from $5.3 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $5.3 million in Q4 2025 and bottomed at -$1.8 million in Q3 2024.
- Historically, Capital Expenditures has averaged $478562.5 across 5 years, with a median of $77000.0 in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 2769.51% in 2024 and fell as far as 10670.59% in 2024.
- Cartesian Therapeutics' Capital Expenditures stood at $1.1 million in 2022, then plunged by 94.03% to $63000.0 in 2023, then jumped by 622.22% to $455000.0 in 2024, then surged by 1074.29% to $5.3 million in 2025, then sank by 99.49% to $27000.0 in 2026.
- Business Quant data shows RNAC's Capital Expenditures at $27000.0 in Q1 2026, $5.3 million in Q4 2025, and -$577000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | 240,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 240,000.00 |
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | 492,000.00 |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 5.51 Mn |
| Jun 30, 2024 | 2.28 Mn |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 130,000.00 |
| Dec 31, 2022 | 211,000.00 |
| Sep 30, 2022 | 436,000.00 |
| Jun 30, 2022 | 99,000.00 |
| Mar 31, 2022 | 455,000.00 |
| Dec 31, 2021 | 278,000.00 |
| Sep 30, 2021 | 164,000.00 |
| Jun 30, 2021 | 618,000.00 |